sinc
begin
centuri
public
health
infrastructur
requir
period
respond
new
reemerg
zoonot
viral
diseas
includ
influenza
ebola
zika
viru
outbreak
sever
acut
respiratori
syndrom
coronaviru
sarscov
first
major
outbreak
centuri
highlight
global
impact
newli
emerg
viru
context
expand
develop
increas
global
poor
public
health
infrastructur
decad
later
emerg
continu
outbreak
middl
east
respiratori
syndrom
coronaviru
merscov
illustr
ongo
threat
pose
circul
zoonot
virus
togeth
outbreak
earli
part
centuri
argu
continu
prepar
vigil
need
maintain
global
public
health
despit
spontan
emerg
sever
research
approach
rapidli
respond
even
predict
outbreak
strain
alreadi
exist
merscov
outbreak
group
other
abl
leverag
reagent
gener
relat
group
coronavirus
name
reagent
creat
independ
viabl
viru
replic
provid
valuabl
insight
model
test
serolog
respons
earli
stage
merscov
outbreak
similarli
revers
genet
system
permit
explor
zoonot
coronavirus
use
known
sar
receptor
interact
chimer
virus
contain
backbon
bat
cov
gener
evalu
efficaci
vaccin
therapeut
invers
approach
place
zoonot
spike
protein
context
epidem
sarscov
backbon
studi
provid
insight
potenti
threat
circul
bat
well
efficaci
current
therapeut
treatment
far
comprehens
result
indic
approach
reagent
predict
may
prove
use
prepar
futur
cov
outbreak
studi
extend
examin
zoonot
virus
novel
merslik
cov
strain
isol
ugandan
bat
name
cov
mersuganda
initi
attempt
cultiv
chimer
merscov
contain
ugandan
merslik
spike
produc
viral
subgenom
transcript
fail
result
infecti
viru
electropor
howev
current
studi
demonstr
exogen
trypsin
treatment
produc
hightit
viru
capabl
plaqu
format
continu
replic
result
consist
recoveri
enter
cov
like
porcin
epidem
diarrhea
viru
previous
describ
major
barrier
batderiv
cov
chimer
ugandan
merslik
spike
viru
could
replic
effici
vero
cell
context
trypsincontain
media
fail
produc
infect
either
continu
primari
human
respiratori
cell
cultur
importantli
mersuganda
chimer
viru
success
infect
cell
human
digest
tract
potenti
identifi
anoth
rout
crossspeci
transmiss
emerg
notabl
blockad
human
receptor
merscov
signific
impact
replic
chimer
mersuganda
viru
suggest
use
altern
receptor
similarli
addit
trypsin
also
rescu
replic
fulllength
relat
group
bat
cov
show
replic
defect
blockad
togeth
result
indic
proteolyt
activ
spike
protein
potent
constraint
infect
zoonot
cov
expand
correl
cov
emerg
beyond
receptor
bind
alon
articl
submit
onlin
preprint
archiv
demonstr
infect
replic
next
sought
determin
capac
mersuganda
chimer
viru
grow
human
cell
previous
merscov
shown
replic
effici
cell
liver
cell
line
infect
mersuganda
rfp
chimer
viru
result
rfpposit
cell
cell
fusion
fig
contrast
rfpposit
cell
observ
nontrypsintr
group
neither
expand
rfp
express
cytopath
effect
seen
absenc
trypsin
observ
may
result
residu
trypsin
activ
undilut
viru
stock
result
lowlevel
infect
explor
n
protein
analysi
western
blot
indic
spike
chimera
could
produc
signific
viral
protein
presenc
trypsin
fig
low
level
protein
observ
controltr
infect
replic
mersuganda
chimera
equival
wildtyp
merscov
result
clearli
demonstr
capac
spike
mediat
infect
human
cell
presenc
trypsin
next
examin
capac
mersuganda
spike
infect
human
respiratori
cell
primari
target
sarscov
merscov
common
coldcaus
human
cov
use
cell
human
lung
epitheli
cell
line
observ
robust
replic
wildtyp
merscov
base
rfp
express
consist
previou
studi
howev
evid
infect
note
mersugandainfect
cell
presenc
absenc
trypsin
subsequ
explor
infect
primari
human
airway
epitheli
hae
cultur
grown
airliquid
interfac
hae
cultur
propens
facilit
improv
infect
sever
human
cov
may
permiss
infect
spike
chimera
infect
chimer
viru
grown
presenc
trypsin
inocul
onto
apic
surfac
hae
cultur
cultur
subsequ
wash
phosphatebuff
salin
pb
contain
trypsin
hour
postinfect
minut
remov
follow
infect
evid
rfp
express
observ
even
trypsin
wash
apic
surfac
fig
similarli
rna
express
analysi
found
evid
accumul
viral
genom
rna
indic
evid
replic
hae
cultur
fig
contrast
wildtyp
merscov
effici
infect
hae
cultur
demonstr
rfp
express
viral
genom
rna
accumul
togeth
hae
result
suggest
spike
unabl
infect
respiratori
cell
human
even
presenc
exogen
trypsin
next
evalu
capac
chimera
infect
cell
digest
tract
uncommon
human
sever
anim
cov
shown
caus
sever
diseas
via
enter
pathway
addit
bat
cov
sequenc
includ
isol
bat
guano
sampl
suggest
enter
etiolog
importantli
presenc
trypsin
solubl
host
proteas
digest
tract
may
facilit
infect
spike
human
test
question
infect
cell
human
epitheli
colorect
adenocarcinoma
cell
line
wildtyp
merscov
mersuganda
spike
chimera
presenc
absenc
trypsin
fig
merscov
infect
cell
result
robust
infect
spread
without
trypsin
media
mersuganda
chimera
addit
trypsin
facilit
infect
mani
rfpposit
cell
howev
infect
robust
wildtyp
merscov
infect
examin
n
protein
western
blot
indic
mersuganda
spike
could
produc
infect
cell
confirm
replic
level
lower
wildtyp
merscov
fig
togeth
result
indic
human
cell
includ
gut
cell
support
infect
mersuganda
chimera
presenc
trypsin
absenc
infect
human
respiratori
cell
coupl
signific
chang
rbd
suggest
mersuganda
util
merscov
receptor
human
entri
explor
question
util
antibodi
block
vero
cell
determin
effect
mersuganda
chimer
viru
replic
expect
antibodi
success
ablat
replic
wildtyp
merscov
presenc
absenc
trypsin
treatment
measur
rfp
n
protein
express
fig
b
contrast
human
antibodi
impact
infect
mersuganda
chimera
viru
presenc
trypsin
confirm
merscov
receptor
requir
mediat
infect
spike
togeth
result
indic
mersuganda
spike
infect
human
cell
requir
human
mediat
infect
establish
replic
capac
human
cell
next
sought
determin
therapeut
develop
merscov
spike
could
disrupt
infect
mersuganda
spike
chimera
sever
monoclon
antibodi
identifi
possibl
therapeut
option
treatment
merscov
includ
first
evalu
potent
antibodi
bind
adjac
spike
rbd
merscov
howev
major
chang
rbd
region
mersuganda
spike
predict
lack
efficaci
fig
potent
neutral
wildtyp
merscov
grown
presenc
absenc
trypsin
fig
howev
consist
expect
antibodi
impact
infect
mersuganda
chimera
fail
neutral
bat
spikeexpress
viru
fig
subsequ
examin
second
monoclon
antibodi
previous
map
conserv
portion
region
mersspik
fig
epitop
rel
conserv
mersuganda
spike
test
efficaci
zoonot
spike
chimera
howev
result
demonstr
neutral
mersuganda
spike
viru
antibodi
fig
notabl
also
fail
neutral
wildtyp
merscov
grown
presenc
exogen
trypsin
fig
togeth
result
indic
group
cov
spike
could
escap
neutral
antibodi
presenc
exogen
trypsin
overal
experi
suggest
antibodi
target
merscov
even
region
highli
conserv
domain
may
util
virus
express
spike
base
mersuganda
chimera
viru
wonder
similar
barrier
prevent
replic
zoonot
cov
previous
group
gener
fulllength
infecti
clone
anoth
group
coronaviru
sequenc
isol
bat
similar
mersuganda
chimera
infecti
clone
produc
subgenom
transcript
fail
achiev
product
infect
revisit
fulllength
recombin
viru
sought
determin
trypsin
treatment
could
also
rescu
follow
infect
addit
trypsin
media
result
cytopath
effect
cell
fusion
contrast
cultur
lack
trypsin
show
sign
viral
infect
explor
viral
genom
rna
trypsin
cultur
media
permit
robust
infect
increas
time
absent
cell
treat
trypsin
fig
similarli
trypsin
media
also
permit
accumul
proteolyt
cleavag
spike
protein
dose
timedepend
manner
fig
importantli
addit
antibodi
impact
infect
suggest
use
differ
receptor
use
wildtyp
merscov
similar
find
mersuganda
spike
fig
togeth
result
demonstr
proteas
cleavag
also
primari
barrier
infect
vero
cell
examin
compar
predict
cleavag
border
endosom
cystein
proteas
site
across
mer
spike
fig
site
mer
uganda
maintain
rxxr
cleavag
motif
although
differ
interior
amino
acid
may
alter
effici
sequenc
mer
also
retain
rxxr
motif
howev
uganda
spike
lack
first
arginin
snar
potenti
impact
cleavag
final
three
spike
maintain
aromat
residu
posit
two
endosom
cystein
proteas
ecp
site
howev
spike
maintain
n
posit
similar
mer
mutant
previous
shown
inactiv
cathepsin
l
activ
togeth
result
suggest
potenti
sequenc
chang
proteas
cleavag
site
may
contribut
trypsin
depend
mersuganda
spikemedi
infect
manuscript
expand
examin
circul
zoonot
virus
identifi
proteas
cleavag
import
barrier
emerg
group
zoonot
cov
chimer
viru
contain
spike
protein
capabl
replic
vero
cell
human
cell
treat
exogen
trypsin
howev
neither
continu
primari
human
airway
cultur
suscept
infect
contrast
wildtyp
merscov
mersuganda
chimera
also
maintain
replic
despit
treatment
antibodi
block
human
suggest
use
either
altern
receptor
differ
entri
mechan
infect
importantli
current
therapeut
target
mer
spike
protein
show
efficaci
mersuganda
chimera
highlight
potenti
public
health
vulner
relat
group
cov
final
trypsinmedi
rescu
second
zoonot
group
cov
valid
find
suggest
proteas
cleavag
may
repres
critic
barrier
zoonot
cov
infect
new
host
togeth
result
highlight
import
spike
process
cov
infect
expand
correl
associ
emerg
beyond
receptor
bind
alon
provid
platform
strategi
recov
previous
noncultivat
zoonot
cov
ongo
threat
pose
circul
zoonot
virus
understand
barrier
viral
emerg
repres
critic
area
research
cov
receptor
bind
believ
primari
constraint
infect
new
host
popul
follow
sarscov
outbreak
emerg
human
attribut
mutat
within
receptorbind
domain
distinguish
epidem
strain
progenitor
virus
harbor
bat
civet
yet
work
group
other
indic
zoonot
sarslik
virus
circul
southeast
asian
bat
capabl
infect
human
cell
bind
known
human
receptor
without
adapt
similarli
pseudotyp
viru
studi
identifi
zoonot
strain
capabl
bind
human
without
mutat
spike
studi
demonstr
spike
capabl
bind
infect
human
cell
prime
trypsin
cleavag
togeth
result
argu
sever
circul
zoonot
cov
strain
capac
bind
human
cell
without
adapt
receptor
bind
may
barrier
cov
emerg
data
studi
implic
process
spike
protein
critic
factor
cov
infect
absenc
trypsin
mersuganda
spike
unabl
mediat
infect
initi
suggest
lack
receptor
compat
howev
exogen
trypsin
treatment
produc
robust
infect
indic
despit
bind
human
cell
cov
overcom
incomplet
spike
process
evalu
zoonot
viru
popul
emerg
threat
must
also
consid
capac
cov
spike
activ
addit
receptor
bind
exogen
process
spike
well
describ
necessari
enter
cov
spike
process
consid
primari
barrier
bat
cov
despit
enter
origin
new
paradigm
bat
cov
combin
receptor
bind
proteolyt
activ
endogen
proteas
permit
zoonot
cov
infect
merscov
sarscov
fig
absenc
receptor
bind
fig
compat
host
proteas
activ
fig
restrict
infect
certain
zoonot
strain
like
barrier
overcom
addit
exogen
proteas
disrupt
need
host
proteas
permit
receptordepend
receptorindepend
entri
fig
overal
new
paradigm
argu
receptor
bind
proteas
activ
barrier
must
overcom
success
zoonot
cov
infect
new
host
requir
exogen
trypsin
treatment
uniqu
mersuganda
influenza
strain
well
known
requir
trypsin
treatment
facilit
releas
cell
cultur
addit
highli
pathogen
avian
influenza
strain
link
mutat
improv
cleavag
ubiquit
host
proteas
augment
tissu
tropism
virul
similarli
wealth
enter
virus
includ
polio
cowpox
rotavirus
depend
trypsin
prime
modul
andor
expand
infect
even
within
cov
famili
enter
virus
includ
porcin
epidem
diarrhea
viru
pedv
porcin
delta
cov
swine
acut
diarrhea
syndrom
sad
cov
requir
trypsin
replic
vitro
togeth
prior
studi
illustr
import
proteas
activ
viru
infect
howev
proteas
barrier
spikemedi
infect
may
also
reflect
emerg
sarscov
merscov
initi
studi
argu
receptor
bind
primari
barrier
exist
zoonot
strain
capabl
effici
use
human
entri
receptor
contradict
suggest
possibl
emerg
epidem
cov
strain
also
requir
modifi
proteas
cleavag
either
human
intermedi
host
camel
civet
addit
increas
receptorbind
affin
consist
idea
report
detail
differenti
infect
merscov
base
host
proteas
express
similarli
mous
adapt
merscov
result
spike
modif
alter
proteas
activ
entri
vivo
coupl
augment
replic
protein
product
wildtyp
merscov
presenc
trypsin
result
suggest
proteolyt
cleavag
epidem
mercov
could
still
enhanc
potenti
augment
cell
surfac
entri
mechan
previous
describ
sarscov
group
bat
cov
strain
requir
trypsin
infect
differ
proteas
activ
may
contribut
infect
chang
rel
epidem
sarscov
context
find
expand
import
proteas
cleavag
criterion
consid
zoonot
viru
emerg
new
host
popul
evalu
threat
human
pose
result
demonstr
pathway
emerg
neither
cov
spike
use
human
entri
chimera
fail
replic
human
respiratori
model
even
presenc
trypsin
mani
differ
proteas
promot
cov
entri
futur
studi
must
determin
proteas
treatment
compon
promot
viru
replic
hae
cultur
howev
replic
cell
indic
human
infect
compat
may
portend
differenti
tropism
possibl
alimentari
biliari
tract
describ
sever
mammalian
cov
mersuganda
could
util
trypsinrich
environ
gut
emerg
enter
pathogen
human
although
patholog
virul
would
hard
predict
evid
sarscov
merscov
outbreak
suggest
involv
enter
pathway
infect
replic
gut
might
select
mutat
expand
spike
processingtrop
allow
replic
tissu
includ
lung
lead
virul
diseas
new
host
popul
seen
porcin
respiratori
coronaviru
examin
threat
pose
must
consid
emerg
cov
tissu
lung
harbor
distinct
patholog
compar
epidem
sar
merscov
receptor
dynam
mersuganda
also
remain
unclear
context
studi
presenc
trypsin
neither
spike
protein
requir
merscov
receptor
entri
consist
differ
receptorbind
domain
bat
epidem
strain
therefor
surpris
antibodi
target
rbd
merscov
spike
ineffect
block
infect
chimera
howev
antibodi
also
efficaci
mersuganda
despit
rel
conserv
bind
epitop
result
possibl
explain
differ
amino
acid
sequenc
merscov
epitop
specif
residu
associ
escap
mutant
merscov
altern
antibodi
also
fail
neutral
wildtyp
merscov
grown
presenc
trypsin
indic
entri
still
possibl
despit
treatment
antibodi
bind
domain
result
suggest
trypsin
treatment
may
permit
conform
chang
either
mask
epitop
facilit
fusionentri
prior
antibodi
bind
convers
presenc
trypsin
may
prime
receptorindepend
entri
mersuganda
chimera
similar
jhvm
strain
mhv
yet
result
would
contrast
pedv
requir
receptor
bind
prior
trypsin
activ
facilit
infect
importantli
lack
infect
respiratori
cell
suggest
receptor
attach
factor
necessari
mediat
entri
spike
recent
work
merscov
bind
sialic
acid
support
idea
indic
spike
may
similar
bind
motif
overal
experiment
studi
requir
fulli
understand
receptor
dynam
spike
provid
new
strategi
recov
zoonot
cov
manuscript
highlight
proteolyt
cleavag
spike
major
barrier
group
zoonot
cov
infect
mersuganda
addit
exogen
trypsin
rescu
infect
indic
spike
cleavag
receptor
bind
limit
strain
new
host
tissu
adapt
proteas
cleavag
site
infect
tissu
robust
host
proteas
express
could
permit
two
zoonot
cov
strain
emerg
may
pose
threat
public
health
due
absenc
effect
spikebas
therapeut
consid
crossspeci
transmiss
result
use
reconstruct
bat
group
cov
confirm
spike
process
correl
associ
emerg
ad
spike
process
receptor
bind
primari
barrier
offer
new
framework
evalu
threat
emerg
zoonot
cov
strain
vero
cell
grown
dulbecco
modifi
eagl
medium
dmem
gibco
ca
supplement
fetalclon
ii
hyclon
ut
antibioticantimycot
antianti
gibco
cell
grown
dmem
supplement
fetalclon
ii
antianti
cell
grown
mem
gibco
supplement
fetal
bovin
serum
hyclon
antianti
human
airway
epitheli
cell
hae
cultur
obtain
univers
north
carolina
unc
cystic
fibrosi
cf
center
tissu
procur
cell
cultur
core
human
lung
procur
univers
north
carolina
chapel
hill
institut
review
boardapprov
protocol
wildtyp
merscov
chimer
mersuganda
cultur
vero
cell
optimem
gibco
supplement
antianti
indic
experi
trypsin
gibco
ad
unless
otherwis
indic
gener
wildtyp
merscov
mersuganda
virus
util
revers
genet
previous
describ
mersuganda
chimera
express
rfp
util
merscov
backbon
replac
rfp
previous
describ
synthet
construct
chimer
mutant
fulllength
mersuganda
approv
univers
north
carolina
institut
biosafeti
committe
replic
vero
hae
cell
perform
previous
describ
briefli
cell
wash
pb
inocul
viru
mock
dilut
optimem
minut
follow
inocul
cell
wash
three
time
fresh
medium
without
trypsin
ad
signifi
time
zero
three
biolog
replic
harvest
describ
time
point
hae
cultur
apic
surfac
wash
pb
contain
trypsin
hour
postinfect
sampl
collect
conduct
blind
manner
sampl
random
microscopi
photo
captur
via
keyenc
microscop
antibodi
neutral
assay
merscov
mersuganda
stock
grown
optimem
without
trypsin
stock
quantifi
via
plaqu
assay
overlay
cell
agaros
optimem
supplement
trypsin
antianti
mersuganda
stock
grown
without
trypsin
low
titer
suffici
neutral
assay
block
experi
vero
cell
preincub
serumfre
optimem
contain
antihuman
antibodi
r
system
mn
hour
medium
remov
cell
infect
hour
viru
mock
inoculum
multipl
infect
inoculum
remov
cell
wash
three
time
pb
medium
replac
rna
isol
via
trizol
reagent
invitrogen
ca
directzol
rna
miniprep
kit
zymo
research
ca
accord
manufactur
protocol
merscov
mersuganda
genom
rna
grna
quantifi
via
taqman
fast
viru
master
mix
appli
biosystem
ca
use
previous
report
primer
probe
target
normal
host
rrna
appli
biosystem
rna
first
revers
transcrib
use
superscript
iii
invitrogen
assay
use
ssofast
evagreen
supermix
biorad
ca
scale
host
dehydrogenas
gapdh
transcript
level
grna
amplifi
follow
primer
forward
revers
gapdh
rna
amplifi
follow
primer
forward
revers
fold
chang
calcul
use
threshold
cycl
method
scale
rna
present
hour
postinfect
viru
replicon
particl
vrp
express
merscov
nucleocapsid
mersuganda
spike
cov
spike
construct
use
nonselect
agent
biosafeti
level
venezuelan
equin
enceph
viru
veev
strain
replicon
system
previous
describ
briefli
rna
contain
nonstructur
gene
veev
either
merscov
nucleocapsid
cov
spike
packag
use
helper
rna
encod
veev
structur
protein
describ
previous
sixweekold
femal
balbc
mice
prime
boost
vrp
gener
mous
antisera
toward
either
merscov
nucleocapsid
cov
spike
follow
vaccin
mous
polyclon
sera
collect
describ
previous
western
blot
lysat
infect
cell
prepar
describ
detail
blot
probe
use
indic
mous
polyclon
sera
merscov
n
sera
abl
detect
n
protein
via
western
blot
previous
describ
plaqu
reduct
neutral
titer
assay
perform
previous
character
antibodi
merscov
previous
describ
briefli
antibodi
serial
dilut
incub
pfu
indic
virus
h
viru
antibodi
ad
plate
confluent
vero
cell
triplic
hour
incub
cell
overlaid
ml
agaros
optimem
supplement
trypsin
antianti
plate
incub
day
merscov
mersuganda
respect
stain
neutral
red
h
plaqu
count
percentag
plaqu
reduct
calcul
number
plaqu
antibodynumb
plaqu
without
antibodi
report
studi
initi
univers
north
carolina
institut
biosafeti
committe
approv
experiment
protocol
work
studi
perform
approv
standard
oper
procedur
sop
safeti
condit
merscov
relat
cov
institut
cov
facil
design
conform
safeti
requir
recommend
biosafeti
microbiolog
biomed
laboratori
bmbl
us
depart
health
human
servic
public
health
servic
center
diseas
control
prevent
cdc
nation
institut
health
nih
laboratori
safeti
plan
submit
facil
approv
use
unc
depart
environment
health
safeti
eh
cdc
nearli
complet
genom
sequenc
merscov
emc
genbank
access
number
genbank
access
number
previous
deposit
genbank
